Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products

Contributed by: Business Wire

Logo

Tags

Research

Infectious Diseases

FDA

Neurology

Biotechnology

Health

Pharmaceutical

Science

Oncology

Earnings

More Like This

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline

Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance

Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

PR Newswire associated0

Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance

Calliditas Interim Report January - September 2023